Department of Medicine, University of Virginia, Box 801355, Charlottesville, VA, 22908, USA.
Department of Otolaryngology, University of Virginia, Charlottesville, VA, USA.
J Clin Immunol. 2018 Apr;38(3):225-233. doi: 10.1007/s10875-018-0476-0. Epub 2018 Feb 17.
Although small prior studies have suggested that IgE can be low in common variable immunodeficiency (CVID), the workup for patients with recurrent infections and suspected hypogammaglobulinemia does not include the routine measurement of serum IgE. We sought to test the hypothesis that low/undetectable serum IgE is characteristic of CVID by comparing the frequency of low/undetectable serum IgE in healthy controls and patients with CVID. We measured total serum IgE in a large multi-center cohort of patients with CVID (n = 354) and compared this to large population-based cohorts of children and adults. We further compared IgE levels in patients with CVID to those with other forms of humoral immunodeficiency, and in a subset, measured levels of allergen-specific serum IgE and IgG subclasses. Lastly, we evaluated for the presence of IgE in commercially available immunoglobulin replacement therapy (IgRT) products. An undetectable serum IgE (< 2 IU/ml) occurs in only 3.3% (95% CI, 1.9-5.7%) of the general population. In contrast, an undetectable IgE occurs in 75.6% (95% CI, 65.6-85.7%) of patients with CVID. Conversely, a high IgE (> 180 IU/ml) is very uncommon in CVID (0.3% of patients). IgE is > 2 IU/ml in 91.2% of patients with secondary hypogammaglobulinemia, and thus, an IgE < LLOD is suggestive of a primary humoral immunodeficiency. Allergen-specific IgE is not detectable in 96.5% of patients with CVID. Sufficient quantities of IgE to change the total serum IgE are not contained in IgRT. The IgG1/IgG4 ratio is increased in subjects with low IgE, regardless of whether they are controls or have CVID. These findings support the routine measurement of serum IgE in the workup of patients with hypogammaglobulinemia.
虽然先前的一些小型研究表明,在常见可变免疫缺陷症(CVID)中 IgE 可能较低,但对反复感染和疑似低丙种球蛋白血症患者的检查并不包括常规测量血清 IgE。我们试图通过比较健康对照者和 CVID 患者中低/无法检测到的血清 IgE 的频率来检验低/无法检测到的血清 IgE 是 CVID 特征的假设。我们在一个大型多中心 CVID 患者队列(n=354)中测量了总血清 IgE,并将其与儿童和成人的大型人群队列进行了比较。我们进一步比较了 CVID 患者的 IgE 水平与其他形式的体液免疫缺陷患者的 IgE 水平,并在一部分患者中测量了过敏原特异性血清 IgE 和 IgG 亚类的水平。最后,我们评估了商业上可获得的免疫球蛋白替代治疗(IgRT)产品中 IgE 的存在。无法检测到的血清 IgE(<2IU/ml)仅发生在普通人群的 3.3%(95%CI,1.9-5.7%)中。相比之下,在 CVID 患者中,无法检测到 IgE 的发生率为 75.6%(95%CI,65.6-85.7%)。相反,在 CVID 中,高 IgE(>180IU/ml)非常罕见(0.3%的患者)。在继发性低丙种球蛋白血症患者中,IgE>2IU/ml 见于 91.2%的患者,因此,IgE<LLOQ 提示为原发性体液免疫缺陷。在 96.5%的 CVID 患者中,无法检测到过敏原特异性 IgE。IgRT 中不包含足以改变总血清 IgE 的 IgE 量。无论他们是对照者还是患有 CVID,低 IgE 者的 IgG1/IgG4 比值均增加。这些发现支持在低丙种球蛋白血症患者的检查中常规测量血清 IgE。